Volume : 13, Issue : 06, June – 2026

Title:

CLINICAL PARADIGMS IN CHRONIC LIVER DISEASE: A COMPREHENSIVE REVIEW OF MEDICATION ADHERENCE, QUALITY OF LIFE, COMPLICATIONS, AND PHARMACOTHERAPEUTIC INTERVENTIONS

Authors :

Shifana K.S, Aleena Anson, Anjana A, Jasna Mariyam T.N, Mrs. Rajasree S, Dr. T. Tamilselvan

Abstract :

Chronic Liver Disease (CLD) is a significant worldwide health burden which includes a variety of diseases such as liver cirrhosis, viral hepatitis, and metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD). A multifaceted strategy that includes strict medication adherence, proactive care of crippling consequences, nutritional optimisation, and the mitigation of drug-related issues is needed to optimise patient results.This review examines the clinical evidence on the impact of non-adherence on disease progression, patient-reported quality of life (HRQoL), systemic consequences such as hepatic encephalopathy and pruritus, and the critical significance of structured educational and nutritional interventions. This research provides actionable ways to reduce repeated hospital admissions and enhance survival in ambulatory and hospitalised CLD populations by analysing current pharmacotherapies in conjunction with clinical pharmacist-led monitoring.
Keywords: Chronic liver disease; medication adherence; quality of life; liver cirrhosis; hepatic encephalopathy; drug-related problems; nutritional counseling; pharmacotherapeutic interventions.

Cite This Article:

Please cite this article in press Shifana K.S et al Clinical Paradigms In Chronic Liver Disease: A Comprehensive Review Of Medication Adherence, Quality Of Life, Complications, And Pharmacotherapeutic Interventions, Indo Am. J. P. Sci, 2026; 13(06).

REFERENCES:

1. Jüngst C, Gräber S, Simons S, Wedemeyer H, Lammert F. Medication adherence among patients with chronic diseases: a survey-based study in pharmacies. QJM. 2019;112(7):505-512.
2. Allard NL, MacLachlan JH, Dev A, Dwyer J, Srivatsa G, Spelman T, Thompson AJ, Cowie BC. Adherence in chronic hepatitis B: associations between medication possession ratio and adverse viral outcomes. BMC Gastroenterol. 2020;20(1):140.
3. Fu KY, Hsieh ML, Chen JA, Hsieh VC. Association between medication adherence and disease outcomes in patients with hepatitis B-related cirrhosis: a population-based case-control study. BMJ Open. 2022;12(6):e059856.
4. Hayward KL, Valery PC, Martin JH, Karmakar A, Patel PJ, Horsfall LU, Tallis CJ, Stuart KA, Wright PL, Smith DD, Irvine KM, Powell EE, Cottrell WN. Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. World J Gastroenterol. 2017;23(40):7321-7331.
5. Afkhami S, Asadi F, Emami H, Sabahi A. The Morisky Method for Measuring Medication Adherence in Older Adults With Chronic Diseases: A Cross-Sectional Study. Health Sci Rep. 2025;8(5):e70681.
6. Shin JW, Jung SW, Lee SB, Lee BU, Park BR, Park EJ, Park NH. Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir. Am J Gastroenterol. 2018;113(7):998-1008.
7. Aller de la Fuente R. Nutrition and Chronic Liver Disease. Clin Drug Investig. 2022;42(Suppl 1):55-61.
8. Ohikere K, Wong RJ. Hepatic Encephalopathy: Clinical Manifestations. Clin Liver Dis. 2024;28(2):253-263.
9. Guo W, Ge X, Lu J, Xu X, Gao J, Wang Q, Song C, Zhang Q, Yu C. Diet and Risk of Non-Alcoholic Fatty Liver Disease, Cirrhosis, and Liver Cancer: A Large Prospective Cohort Study in UK Biobank. Nutrients. 2022;14(24):5335.
10. Younossi ZM, Kremer AE, Swain MG, Jones D, Bowlus C, Trauner M, Henry L, Gerber L. Assessment of fatigue and its impact in chronic liver disease. J Hepatol. 2024;81(4):726-742.
11. Ghabril M, Vuppalanchi R, Chalasani N. Drug-Induced Liver Injury in Patients With Chronic Liver Disease. Liver Int. 2025;45(3):e70019.
12. Andrade LF, Haq Z, Abdi P, Diaz MJ, Levy C, Yosipovitch G. Association of Liver Disease and Chronic Pruritus: A Case-Control Study. Liver Int. 2025;45(4):e16126.
13. Effandie E, Gupte GL. Chronic Liver Disease – What’s New? Indian J Pediatr. 2024;91(4):391-397.
14. De Siervi S, Cannito S, Turato C. Chronic Liver Disease: Latest Research in Pathogenesis, Detection and Treatment. Int J Mol Sci. 2023;24(13):10633.
15. Zhong J, Cai Z, Zhu G, Zhang J. Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction-associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta-analysis. Diabetes Obes Metab. 2025;27(6):3309-3323.
16. Younossi ZM, Stepanova M, Schattenberg JM, Henry L. Measuring health-related quality of life and patient-reported outcomes in chronic liver disease. J Hepatol. 2026;84(2):457-472.
17. Cortesi PA, Conti S, Scalone L, Jaffe A, Ciaccio A, Okolicsanyi S, Rota M, Fabris L, Colledan M, Fagiuoli S, Belli LS, Cesana G, Strazzabosco M, Mantovani LG. Health related quality of life in chronic liver diseases. Liver Int. 2020;40(11):2630-2642.
18. Fadlallah H, El Masri D, Bahmad HF, Abou-Kheir W, El Masri J. Update on the Complications and Management of Liver Cirrhosis. Med Sci (Basel). 2025;13(1):13.
19. Assimakopoulos K, Karaivazoglou K, Tsermpini EE, Diamantopoulou G, Triantos C. Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. J Psychosom Res. 2018;112:73-80.
20. Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, Ruckes C, Galle PR, Romero-Gómez M, Anstee QM, Schattenberg JM; EPoS Consortium Investigators. Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clin Gastroenterol Hepatol. 2019;17(10):2085-2092.e1.
21. Gungabissoon U, Hunnicutt J, McDermott EJ, Lovley A, Frazer MS, LaGasse KM, Kosinski M, McCausland KL, McGirr A, Smith HT, Hirschfield GM, Trivedi P. Pruritus and health-related quality of life in chronic liver disease: a longitudinal, survey-based cohort study. BMJ Open Gastroenterol. 2025;12(1):e001809.
22. Gazineo D, Godino L, Bui V, El Mouttaqi L, Franciosi E, Natalino A, Ceci G, Ambrosi E. Health-related quality of life in outpatients with chronic liver disease: a cross-sectional study. BMC Gastroenterol. 2021;21(1):318.
23. Aspinall RJ. Reducing recurrent hospital admissions in patients with decompensated cirrhosis. Br J Hosp Med (Lond). 2018;79(2):93-96.
24. Oikonomou A, Fotos N, Chatziefstratiou AA, Giakoumidakis K, Elefsiniotis I, Brokalaki H. The Effect of Educational Intervention on Adherence to Treatment Recommendations and Quality of Life in Patients With Liver Cirrhosis. Cureus. 2025;17(4):e81737.
25. Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer AJ, Wong F, Fung S, Sherman M, Manns MP, Cornberg M, Hansen BE, Wedemeyer H, Janssen HL, de Knegt RJ, Feld JJ. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol. 2016;14(12):1821-1830.e6.
26. Twinkle MJS, Karjal RZ, Anushree A, Kellarai A, Shaji B, Shetty S, Ramkumar P, Joel JJ. Assessment of Drug-related Problems among Patients of Chronic liver Disease in a Tertiary Care Hospital. Ethiop J Health Sci. 2024;34(6):459-468.
27. Lv L, Lin XQ, Chen Y, Chen HD, Zhang MX, Shao H, Tung TH, Zhu JS. Adverse reactions to inactivated COVID-19 vaccination in patients with chronic liver disease: The effect of anxiety. Hum Vaccin Immunother. 2022;18(6):2136435.
28. Guo W, Ge X, Lu J, Xu X, Gao J, Wang Q, Song C, Zhang Q, Yu C. Diet and Risk of Non-Alcoholic Fatty Liver Disease, Cirrhosis, and Liver Cancer: A Large Prospective Cohort Study in UK Biobank. Nutrients. 2022;14(24):5335.
29. Sileno S, Chirila RM, Harris DM. Use of statins, amiodarone, direct oral anticoagulants and NSAIDs in chronic liver disease: a guide for general clinicians. Rom J Intern Med. 2020;58(4):181-187.
30. Alemnew Ayal M, Admasu Dessie Y, Eshetie Nega M, Tsegaw Negash W, Mulat Berihun S. Treatment outcomes of chronic liver disease and associated factors among patients treated at hospitals in Bahir Dar city, north-west Ethiopia. BMC Gastroenterol. 2025;25(1):141.
31. Jane A, Vyas M, Kumar A, Verma A, Giresha A, Patel J D. LIVER FIBROSIS: PATHOPHYSIOLOGY, DIAGNOSIS, AND EMERGING THERAPEUTIC TARGETS FOR A COMMON COMPLICATION OF CHRONIC LIVER DISEASES. Georgian Med News. 2023;(340-341):93-100.
32. Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev. 2017;9(9):CD000222.
33. Wagner M, Fickert P. Drug Therapies for Chronic Cholestatic Liver Diseases. Annu Rev Pharmacol Toxicol. 2020;60:503-527.
34. Hanai T, Nishimura K, Unome S, Miwa T, Nakahata Y, Imai K, Suetsugu A, Takai K, Shimizu M. Nutritional counseling improves mortality and prevents hepatic encephalopathy in patients with alcohol-associated liver disease. Hepatol Res. 2024;54(11):1089-1098.
35. Alavinejad P, Hajiani E, Danyaee B, Morvaridi M. The effect of nutritional education and continuous monitoring on clinical symptoms, knowledge, and quality of life in patients with cirrhosis. Gastroenterol Hepatol Bed Bench. 2019;12(1):17-24.